+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab"

Psoriasis Market and Forecast Analysis to 2025 - Product Thumbnail Image

Psoriasis Market and Forecast Analysis to 2025

  • Drug Pipelines
  • July 2018
  • 616 Pages
  • Global
From
From
From
From
Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019 - Product Thumbnail Image

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019

  • Drug Pipelines
  • November 2019
  • 58 Pages
  • Global
From
Global Adalimumab Drugs Market Report and Forecast 2024-2032 - Product Thumbnail Image

Global Adalimumab Drugs Market Report and Forecast 2024-2032

  • Report
  • February 2024
  • 140 Pages
  • Global
From
From
From
From
Loading Indicator

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms. Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients. Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more